Vanguard Group Inc Cyclerion Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.42 - $18.8 $349 - $15,641	832 Added 0.05%	1,651,536 $1.09 Million
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $60,000 - $1.88 Million	-103,449 Reduced 5.9%	1,650,704 $1.42 Million
Q1 2022 May 13, 2022	SELL	$0.96 - $1.78 $111,561 - $206,853	-116,210 Reduced 6.21%	1,754,153 $1.95 Million
Q4 2021 Feb 14, 2022	BUY	$1.56 - $2.99 $683,801 - $1.31 Million	438,334 Added 30.61%	1,870,363 $3.22 Million
Q3 2021 Nov 12, 2021	BUY	$2.73 - $4.13 $23,196 - $35,092	8,497 Added 0.6%	1,432,029 $4.4 Million
Q2 2021 Aug 13, 2021	BUY	$2.18 - $4.29 $3.1 Million - $6.11 Million	1,423,532 New	1,423,532 $5.55 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.